All News

RedHill Biopharma Ltd today announced that it has completed the recently announced acquisition of the global rights to Movantik (naloxegol) for the treatment of opioid-induced constipation (OIC) from AstraZeneca.

Pharmacists working collaboratively can make an impact, including for patients with more acute diseases.

The Department of Health and Human Services said that there are only 5 locations out of 67,000 pharmacy sites with the capacity to test for COVID-19 through the Community-Based Testing Site program.

Today’s pharmacy hero is Shawn Hodges, PharmD, of Innovation Compounding Pharmacy in Kennesaw, Georgia.

Rural community pharmacies evolve to continue serving low-income patients with chronic conditions during the coronavirus disease 2019 pandemic.

The announcement is in response to ongoing reports of contamination with N-Nitrosodimethylamine (NDMA).

The collaboration will combine VBI’s viral vaccine experience and coronavirus antigens with the NRC’s unique COVID-19 antigens and assay development capabilities.

The FDA has announced that it is accelerating the development of potentially safe and effective life-saving treatments for patients with the coronavirus 2019 disease.

New advances in medical therapy have made it possible for rosacea patients to achieve clear skin.

Key best practices for protecting pharmacy personnel during the COVID-19 pandemic.

The prevalence of HIV in jails and prisons is approximately 4 times higher than that of the general United States population.

Genomic profiles measured through circulating free DNA in the blood of patients with breast cancer may provide a more effective way to treat the disease and track its progression.

Study shows rivaroxaban (Xarelto, Bayer) following nonmajor orthopedic surgery reduced the risk of major venous thromboembolism by approximately 75% compared with enoxaparin.

This group of health care professionals has experienced the burdens associated with increased patient demands, the potential for exposure, and shifting role expectations.

The National Association of Boards of Pharmacy Passport is a temporary authorization that facilitates pharmacists and pharmacy technicians practicing in another state.

Patients with symptomatic peripheral artery disease who took rivaroxaban (Xarelto, Bayer) saw a 15% reduction in the risk of major adverse limb and cardiovascular events.

Pharmacists can play an important role in educating patients about poison prevention tips during the pandemic, and discuss the dangers of home remedies.

Pharmacy Times’ parent company will be hosting the virtual MJH Life Sciences Sleeves Up Blood Drive from March 31 through April 30.

A recent study has detailed information on the potential dangers and the application of QTc monitoring to guide treatment when using drugs that can cause heart rhythm changes.

The length of time patients remained contagious after the end of their symptoms, however, ranged from 1 to 8 days.

"We are trying to stay strong, and we couldn’t cope with this situation if it wasn’t for our deep team connection.”

A study by the American Academy of Neurology suggests that taking a low-dose aspirin once per day does not reduce the risk of thinking and memory problems caused by mild cognitive impairment or possible Alzheimer disease.

A new study examining records from the Ohio Health Department from 2010 to 2017 found that white men between the ages of 30 and 39 had the highest risk for fatal opioid overdoses.

While the drugs are not currently FDA-approved for COVID-19, the FDA noted that they are recommended in some countries for COVID-19.

Members of the Society of Infectious Diseases Pharmacists (SIDP) have been on the forefront of the pandemic, reviewing treatment data and assisting in interpretation for clinical use.

How has COVID-19 affected our lives?

Researchers examine how stem cells promote neuronal growth in tissue regeneration and in cancer progression.

In the midst of rapid industry changes and new demands brought by the coronavirus disease 2019 pandemic, pharmacy technicians are taking on new roles and responsibilities.

A prespecified exploratory analysis using the safety data from the 3 trials indicated fewer major adverse cardiovascular events (MACE) with inclisiran compared with placebo.

According to the researchers, the case fatality rate for patients with COVID-19 and cardiovascular disease is 10.5%.